DDInter336 DDInter1329
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™.
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oliceridine
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Celecoxib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oliceridine
Celecoxib {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Celecoxib {u} (Compound) causes {v} (Side Effect) Toxic epidermal necrolysis
Toxic epidermal necrolysis {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Vemurafenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bupropion
Bupropion {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Celecoxib {u} (Compound) downregulates {v} (Gene) TUBB2B
TUBB2B {u} (Gene) is bound by {v} (Compound) Eribulin
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Terbinafine
Terbinafine {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Celecoxib {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Celecoxib {u} (Compound) palliates {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Anagrelide
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Celecoxib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Celecoxib (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Celecoxib (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Vemurafenib (Compound) and Vemurafenib may lead to a major life threatening interaction when taken with Oliceridine
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bupropion (Compound) and Bupropion may lead to a major life threatening interaction when taken with Oliceridine
Celecoxib (Compound) downregulates TUBB2B (Gene) and TUBB2B (Gene) is bound by Eribulin (Compound) and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Terbinafine (Compound) and Terbinafine may lead to a major life threatening interaction when taken with Oliceridine
Celecoxib (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Celecoxib (Compound) palliates hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Anagrelide (Compound) and Anagrelide may lead to a major life threatening interaction when taken with Oliceridine